Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
- Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients inJapan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in 3-5% of non-small c...
2019-11-20 15:00
2116
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Not intended for US, Canada and UK-based media DARMSTADT, Germany and NEW YORK, Feb. 18, 2019 /PRNewswire/ -- * JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression * US FDA has granted Priority Rev...
2019-02-18 07:48
4530
